| 摘要 |
The present invention relates to the use of Hades as a negative modulator of Akt, and more particularly, to a negative modulator of Akt (protein kinase B) or anticancer agent containing, as an active ingredient, the Hades protein or a gene that encodes Hades protein. Akt, which is a serine/threonine-specific protein kinase, functions in a variety of cell processes including cell proliferation, cell survival, and tumor development. The inventors of the present invention have identified Hades as being a negative modulator of Akt and having a RING finger domain and E3 ubiquitin ligase activity. According to the present invention, Akt may directly interact with Hades, and may be ubiquitinated by Hades in vitro and in vivo. Therefore, the Hades of the present invention may decompose Akt and negatively modulate the downstream signaling thereof to inhibit the proliferation and survival of cancer cells, and therefore may be effectively used as an anticancer agent. |
